WO2019017680A3 - miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME - Google Patents

miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME Download PDF

Info

Publication number
WO2019017680A3
WO2019017680A3 PCT/KR2018/008085 KR2018008085W WO2019017680A3 WO 2019017680 A3 WO2019017680 A3 WO 2019017680A3 KR 2018008085 W KR2018008085 W KR 2018008085W WO 2019017680 A3 WO2019017680 A3 WO 2019017680A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkinson
disease
mirna
biomarker
same
Prior art date
Application number
PCT/KR2018/008085
Other languages
French (fr)
Korean (ko)
Other versions
WO2019017680A9 (en
WO2019017680A2 (en
Inventor
류현정
Original Assignee
국민대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170116583A external-priority patent/KR101956315B1/en
Application filed by 국민대학교 산학협력단 filed Critical 국민대학교 산학협력단
Priority to JP2020502648A priority Critical patent/JP7030358B2/en
Priority to EP18834700.9A priority patent/EP3656876A4/en
Priority to US16/631,954 priority patent/US11447772B2/en
Priority to CN201880059124.3A priority patent/CN111344417A/en
Publication of WO2019017680A2 publication Critical patent/WO2019017680A2/en
Publication of WO2019017680A3 publication Critical patent/WO2019017680A3/en
Publication of WO2019017680A9 publication Critical patent/WO2019017680A9/en
Priority to US17/888,084 priority patent/US20220389426A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a method for providing information on the diagnosis of Parkinson's disease. Also, the present invention relates to a composition for preventing, alleviating, or treating Parkinson's disease. The miRNA of the present invention can be effectively availed for diagnosis and treatment of Parkinson's disease as the miRNA shows specifically down- or upregulated expression in a Parkinson's disease model.
PCT/KR2018/008085 2017-07-19 2018-07-17 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME WO2019017680A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2020502648A JP7030358B2 (en) 2017-07-19 2018-07-17 MiRNA as a Parkinson's disease biomarker and a diagnostic kit using it
EP18834700.9A EP3656876A4 (en) 2017-07-19 2018-07-17 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME
US16/631,954 US11447772B2 (en) 2017-07-19 2018-07-17 miRNA as biomarker for Parkinson's disease and diagnostic kit using same
CN201880059124.3A CN111344417A (en) 2017-07-19 2018-07-17 miRNA as Parkinson disease biomarker and diagnostic kit using same
US17/888,084 US20220389426A1 (en) 2017-07-19 2022-08-15 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
KR20170091417 2017-07-19
KR10-2017-0091417 2017-07-19
KR1020170116583A KR101956315B1 (en) 2017-07-19 2017-09-12 miR494 as a biomarker for parkinson’s disease and diagnostic kit using thereof
KR10-2017-0116583 2017-09-12
KR10-2017-0132869 2017-10-12
KR10-2017-0132870 2017-10-12
KR10-2017-0132867 2017-10-12
KR1020170132870A KR102062787B1 (en) 2017-07-19 2017-10-12 miR501 as a biomarker for parkinson’s disease and diagnostic kit using thereof
KR1020170132867A KR101956323B1 (en) 2017-07-19 2017-10-12 miR6768 as a biomarker for parkinson’s disease and diagnostic kit using thereof
KR1020170132868A KR101956328B1 (en) 2017-07-19 2017-10-12 miR4324 as a biomarker for parkinson’s disease and diagnostic kit using thereof
KR10-2017-0132868 2017-10-12
KR10-2017-0132866 2017-10-12
KR1020170132866A KR102063244B1 (en) 2017-07-19 2017-10-12 miR1244 as a biomarker for parkinson’s disease and diagnostic kit using thereof
KR1020170132869A KR101956329B1 (en) 2017-07-19 2017-10-12 miR4726 as a biomarker for parkinson’s disease and diagnostic kit using thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/631,954 A-371-Of-International US11447772B2 (en) 2017-07-19 2018-07-17 miRNA as biomarker for Parkinson's disease and diagnostic kit using same
US17/888,084 Continuation US20220389426A1 (en) 2017-07-19 2022-08-15 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME

Publications (3)

Publication Number Publication Date
WO2019017680A2 WO2019017680A2 (en) 2019-01-24
WO2019017680A3 true WO2019017680A3 (en) 2019-04-18
WO2019017680A9 WO2019017680A9 (en) 2019-05-16

Family

ID=65015773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008085 WO2019017680A2 (en) 2017-07-19 2018-07-17 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME

Country Status (1)

Country Link
WO (1) WO2019017680A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018650A1 (en) * 2012-07-25 2014-01-30 Rush University Medical Center Mirnas as novel therapeutic targets and diagnostic biomarkers for parkinson's disease
WO2014075822A1 (en) * 2012-11-16 2014-05-22 Siemens Aktiengesellschaft New diagnostic mirna markers for parkinson disease
US9297007B2 (en) * 2010-05-28 2016-03-29 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg miRNAs involved in the blood brain barrier function
US20170044529A1 (en) * 2012-12-18 2017-02-16 University Of Washington Through Its Center For Commercialization Methods and Compositions to Modulate RNA Processing
WO2017084770A1 (en) * 2015-11-20 2017-05-26 Braindtech S.R.L. Microglial microvesicles contained microrna-based methods for the diagnosis, prognosis and treatment monitoring of neurological, neurodegenerative and inflammation-based diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
DE68908054T2 (en) 1988-01-21 1994-03-10 Genentech Inc REINFORCEMENT AND DETECTION OF NUCLEIC ACID SEQUENCES.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1990001069A1 (en) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Process for amplifying and detecting nucleic acid sequences
BR8907830A (en) 1988-12-16 1991-10-22 Siska Diagnostics Inc PROCESS FOR PREPARING A DOUBLE-FILAMENT DNA THAT CODES A SEQUENCE THAT MATCHES A OBJECTIVE NUCLEIC ACID SEQUENCE AND PROCESS USED FOR DETECTION OF AT LEAST ONE SPECIFIC OBJECTIVE NUCLEIC ACID SEQUENCE
CA2035010C (en) 1990-01-26 1996-12-10 Keith C. Backman Method of amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297007B2 (en) * 2010-05-28 2016-03-29 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg miRNAs involved in the blood brain barrier function
WO2014018650A1 (en) * 2012-07-25 2014-01-30 Rush University Medical Center Mirnas as novel therapeutic targets and diagnostic biomarkers for parkinson's disease
WO2014075822A1 (en) * 2012-11-16 2014-05-22 Siemens Aktiengesellschaft New diagnostic mirna markers for parkinson disease
US20170044529A1 (en) * 2012-12-18 2017-02-16 University Of Washington Through Its Center For Commercialization Methods and Compositions to Modulate RNA Processing
WO2017084770A1 (en) * 2015-11-20 2017-05-26 Braindtech S.R.L. Microglial microvesicles contained microrna-based methods for the diagnosis, prognosis and treatment monitoring of neurological, neurodegenerative and inflammation-based diseases

Also Published As

Publication number Publication date
WO2019017680A9 (en) 2019-05-16
WO2019017680A2 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
WO2016168784A3 (en) Rna nanoparticles and method of use thereof
MX2016010237A (en) Methods of treating alzheimer's disease.
WO2014133855A8 (en) Tuberculosis biomarkers and uses thereof
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MY179105A (en) Methods of treating alzheimer's disease
WO2019006005A3 (en) Methods and compositions for treating melanoma
EP3736327A4 (en) Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom
WO2015127134A3 (en) Complement component c5 antibodies
MX2009013649A (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma.
EA201791993A1 (en) METHODS OF TREATMENT PROTEINOPATHY
MY187073A (en) Use of a trichothecene-transforming alcohol dehydrogenase, method for transforming trichothecenes and trichotecene-transforming additive
WO2018004224A3 (en) Novel sporichthyaceae microorganism and use thereof
WO2018199530A3 (en) Diagnostic method for behcet's disease using metabolome analysis
EP3558340A4 (en) Methods of using gm6 in diagnosing and treating alzheimer's disease
EP3656876A4 (en) miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
EA202191631A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2020009532A (en) Modified oligonucleotides for use in treatment of tauopathies.
RS54777B1 (en) Process for the biocontrol of pseudomonas
MX2021009247A (en) Methods, systems, and kits for treating inflammatory disease targeting il18r1.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18834700

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020502648

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018834700

Country of ref document: EP

Effective date: 20200219